All this makes sense Avemaria, and I've just bought another few thousand @$2.88, but I'm thinking though that the whole 'we're still not really on anyone's radar yet' thing is starting to wear a bit thin. Retail perhaps yes, but the fundies are well aware of us I'm sure, and big pharmas are surely taking a close look at a company with a blockbuster drug which is trading for a pittance. So why all the lack of interest?
Wondering if perhaps the IP issue is a hotter potato than we thought...
Valuation and Targets, page-223
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |